Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

CureVac N.V. - Ordinary Shares (NQ:CVAC)

4.695 +0.065 (+1.40%)
Streaming Delayed Price Updated: 3:03 PM EDT, Jun 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 490,430
Open 4.650
Bid (Size) 4.690 (4)
Ask (Size) 4.700 (14)
Prev. Close 4.630
Today's Range 4.520 - 4.775
52wk Range 2.370 - 5.280
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Trump Administration Terminates $590 Million Moderna Bird Flu Vaccine Deal, Dismantling Biden-Era Pandemic Preparedness Effort
The Trump administration terminated a nearly $600 million award to Moderna for developing an mRNA-based bird flu vaccine, ending a key Biden-era pandemic preparedness initiative. The cancellation... 
Via Benzinga
Topics Government
Exposures Political
CureVac (CVAC) Stock Rises After Q1 Update, Oncology Pipeline Gains Traction
CureVac stock surged after reporting Q1 2025 results and a positive pipeline update. The biotech firm narrowed its operating loss, and cash is expected to fund operations through 2028. 
Via Benzinga

Performance

YTD
+36.1%
+36.1%
1 Month
+35.3%
+35.3%
3 Month
+43.6%
+43.6%
6 Month
+69.5%
+69.5%
1 Year
+27.9%
+27.9%

More News

Read More
CureVac Announces Financial Results for the First Quarter of 2025 and Provides Business Updates
Via ACCESS Newswire
CureVac Receives Additional Positive Validity Decision from European Patent Office in Ongoing Litigation Against BioNTech SE
Via ACCESS Newswire
CureVac Stock Declines On Weaker-Than-Expected Q4 Revenue: Retail’s On Wait-And-Watch Mode
Via Stocktwits
Topics Government
Exposures Political
Insights Ahead: CureVac's Quarterly Earnings
Via Benzinga
CureVac Earns Repeat Recognition by LexisNexis(R) as One of the World’s Top Innovators
Via ACCESS Newswire
CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2024 and Provides Business Update
Via ACCESS Newswire
Earnings Scheduled For April 10, 2025
Via Benzinga
CureVac to Report Fourth Quarter and Full-Year 2024 Financial Results and Business Update on April 10, 2025
Via ACCESS Newswire
CureVac Receives U.S. FDA IND Clearance to Initiate Phase 1 Clinical Trial for Novel mRNA-Based Precision Immunotherapy in Squamous Non-Small Cell Lung Cancer
Via ACCESS Newswire
Traders are paying attention to the gapping stocks in Friday's session.
Via Chartmill
Why CureVac (CVAC) Stock Is Moving
Via Benzinga
Top movers in Friday's pre-market session
Via Chartmill
Argan Posts Upbeat Results, Joins KULR Technology, Abacus Global Management, W. R. Berkley And Other Big Stocks Moving Higher On Friday
Via Benzinga
European Patent Office Rules Vaccine Developer CureVac's Amended Patent Valid, Stock Jumps
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Wondering what's happening in today's after-hours session?
Via Chartmill
CureVac Receives Positive Validity Decision from European Patent Office in Litigation Against BioNTech SE
Via ACCESS Newswire
Deadly Bird Flu Strain Detected In Nevada Man: 4 Stocks To Watch
Via Benzinga
Trump Administration Halts All Communications From The Centers For Disease Control As Bird Flu Spreads
Via Benzinga
Topics Government
Exposures Political
Bird Flu Update: First Commercial Case In Georgia, Moderna Receives $590 Million To Develop Vaccine
Via Benzinga
Bird Flu Raising Red Flags Among Health Officials, CDC Urges Faster Testing
Via Benzinga
Why CureVac (CVAC) Shares Are Volatile
Via Benzinga
Bird Flu Sparks Vaccine Stock Surge: ETFs To Watch As H5N1 Outbreak Intensifies
Via Benzinga
Topics ETFs
US Records First Human Bird Flu Death, High Levels Of Respiratory Illnesses: Vaccine Stocks Rally
Via Benzinga

Frequently Asked Questions

Is CureVac N.V. - Ordinary Shares publicly traded?
Yes, CureVac N.V. - Ordinary Shares is publicly traded.
What exchange does CureVac N.V. - Ordinary Shares trade on?
CureVac N.V. - Ordinary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for CureVac N.V. - Ordinary Shares?
The ticker symbol for CureVac N.V. - Ordinary Shares is CVAC on the Nasdaq Stock Market
What is the current price of CureVac N.V. - Ordinary Shares?
The current price of CureVac N.V. - Ordinary Shares is 4.695
When was CureVac N.V. - Ordinary Shares last traded?
The last trade of CureVac N.V. - Ordinary Shares was at 06/03/25 03:03 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.